Hematopoietic Stem Cell Transplant

9

Review clinical trials related to Hematopoietic Stem Cell Transplant. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant

Background: Hematopoietic stem cell transplant (HSCT) is a common treatment for many cancers and other illnesses. But many people who have HSCT go on to develop liver dysfunction. Researchers want to know more about how and why this happens. In this natural history study, they will try to learn what factors lead to liver dysfunction; how underlying liver disease may affect the results of HSCT; and how HSCT may contribute to liver dysfunction. Objective: To understand the links between HSCT and liver dysfunction. Eligibility: Adults aged 18 years or older and children 3 to 17 years who are being evaluated for HSCT. Design: This study involves 11 visits in 4 years. Most visits will be in the first year. Before and after their HSCT, participants will undergo these tests: Physical exam, including blood tests and a test of heart function. Participants will provide stool samples. Liver biopsies. Samples of liver tissue will be removed. This may be done either by inserting a needle through the right side of the chest, or with a thin tube threaded to the liver from a vein in the neck. Adult participants will undergo this procedure 2 times: once before the HSCT and once about a year later. Imaging scans. Participants will lie on a bed that moves into either a cylinder or a donut-shaped machine. Ultrasound. Participants will lie still. A probe that uses sound waves will be slid over their skin to get pictures of the liver. Fibroscan exam. This is like an ultrasound that uses a special probe to measure the toughness of the liver. ...

Participants needed: 500
Trial details
Age: 3-90Biological sex: AllType: ObservationalSponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Updated: Jul 13, 2026Locations: 1
Eligibility criteria

Male and female adults >=18 years of age and children 3-17 years of age [+1]

Pregnancy or lactation [+2]

Status: Not yet recruiting

Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant

Background: Hematopoietic stem cell transplant (HSCT) is a common treatment for many cancers and other illnesses. But many people who have HSCT go on to develop liver dysfunction. Researchers want to know more about how and why this happens. In this natural history study, they will try to learn what factors lead to liver dysfunction; how underlying liver disease may affect the results of HSCT; and how HSCT may contribute to liver dysfunction. Objective: To understand the links between HSCT and liver dysfunction. Eligibility: Adults aged 18 years or older and children 3 to 17 years who are being evaluated for HSCT. Design: This study involves 11 visits in 4 years. Most visits will be in the first year. Before and after their HSCT, participants will undergo these tests: Physical exam, including blood tests and a test of heart function. Participants will provide stool samples. Liver biopsies. Samples of liver tissue will be removed. This may be done either by inserting a needle through the right side of the chest, or with a thin tube threaded to the liver from a vein in the neck. Adult participants will undergo this procedure 2 times: once before the HSCT and once about a year later. Imaging scans. Participants will lie on a bed that moves into either a cylinder or a donut-shaped machine. Ultrasound. Participants will lie still. A probe that uses sound waves will be slid over their skin to get pictures of the liver. Fibroscan exam. This is like an ultrasound that uses a special probe to measure the toughness of the liver. ...

Participants needed: 500
Trial details
Age: 3-90Biological sex: AllType: ObservationalSponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Updated: Jul 2, 2026Locations: 1
Eligibility criteria

Male and female adults >=18 years of age and children 3-17 years of age [+1]

Pregnancy or lactation [+2]

Status: Recruiting

Coping Skills Training for Symptom Management and Daily Steps (Step Up)

The aim of this study is to test the efficacy of a hybrid in-person and mHealth coping skills training and activity coaching intervention (Step Up), to enable HCT patients to effectively cope with symptoms (pain, fatigue, and stress) to improve their ability to engage in physical activity that can improve physical disability.

Participants needed: 177
Trial details
Age: 18-99Biological sex: AllType: InterventionalSponsor: Duke UniversityUpdated: Jun 25, 2026Locations: 1
Eligibility criteria

receipt of an autologous (auto) HCT or CAR-T cell therapy due to a hematologic m... [+3]

cognitive impairment (e.g., dementia) recorded in the chart or suspected by prov... [+3]

Status: Not yet recruiting

Meaning-Centered Psychotherapy for Addressing Existential Distress of Patient/Caregiver Dyads Following Hematopoietic Stem Cell Transplantation: Feasibility and Acceptability

The purpose of this study is to learn whether Meaning-Centered Psychotherapy (MCP-Dyad) is practical, acceptable, and helpful to survivors and caregivers during recovery after stem cell transplant. MCP-Dyad is a meaning-focused support program. It is designed to help people stay connected to meaning, cope with difficult experiences, and communicate as a pair during recovery.

Participants needed: 100
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Mayo ClinicUpdated: Jun 22, 2026Locations: 1
Eligibility criteria

Eligible patients and their caregivers must be adults (≥18 years) [+5]

Patients undergoing HSCT for nonmalignant conditions [+3]

Status: Recruiting

Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation

To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipients.

Participants needed: 10
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of Michigan Rogel Cancer CenterUpdated: May 4, 2026Locations: 1
Eligibility criteria

Adult 18 years or older [+5]

Severe anemia (hemoglobin <7 gm/dl) [+8]

Status: Recruiting

Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors

This randomized clinical trial is evaluating the impact of a positive psychology intervention (PATH) on anxiety symptoms, depression symptoms, and quality of life in survivors of hematopoietic stem cell transplant (HSCT) compared to usual care.

Participants needed: 400
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Brigham and Women's HospitalUpdated: Nov 13, 2025Locations: 3
Eligibility criteria

Adult patients (aged 18 years and older) undergoing allogeneic HSCT and are appr... [+2]

Patients who underwent allogeneic HSCT for benign hematologic conditions [+1]

Status: Recruiting

T Cell Therapy of Opportunistic Cytomegalovirus Infection

The purpose of this study is to determine if a specific type of cell-based immunotherapy, using T-cells from a donor that are specific against cytomegalovirus (CMV) is feasible to treat infections by CMV. Adoptive T-cell therapy is an investigational (experimental) therapy that works by using the blood of a donor and selecting the T-cells that can respond against a specific infectious entity. These selected T-cells are then infused to the patient, to try to give the immune system the ability to fight the infection. Adoptive T-cell therapy is experimental because it is not approved by the Food and Drug Administration (FDA).

Participants needed: 20
Trial details
Phase: Early Phase 1Age: 3+Biological sex: AllType: InterventionalSponsor: Mari DallasUpdated: Oct 22, 2025Locations: 1
Eligibility criteria

Patients must have received allogeneic hematopoietic stem cell transplant and be... [+9]

Pregnant or breastfeeding women are excluded from this study. [+9]

Status: Recruiting

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.

Participants needed: 36
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Tr1X, Inc.Updated: Apr 15, 2025Locations: 5
Eligibility criteria

Subjects with one of the following hematologic malignancies: Acute Lymphoblastic... [+9]

Prior allogeneic bone marrow, peripheral blood, or cord blood HSCT. [+8]

Status: Not yet recruiting

A Study of the Effect of Laughter Therapy on the Mental Health and Quality of Survival of Hematopoietic Stem Cell Transplant Patients

主要研究目的: 1)探讨笑疗法在造血干细胞移植患者移植心理健康及生存质量中的效果。 次要研究目的: 1. 了解造血干细胞移植患者移植后3个月、6个月、1年内的心理健康变化和生存质量水平; 2. 探讨笑疗法在造血干细胞移植患者预后等结局指标中的应用效果。

Participants needed: 98
Trial details
Age: 16+Biological sex: AllType: InterventionalSponsor: Institute of Hematology & Blood Diseases Hospital, ChinaUpdated: Jan 24, 2025
Eligibility criteria

Not listed